Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av NIS793 og andre nye undersøkelseskombinasjoner med SOC anti-kreftterapi for 2L-behandling av mCRC (daNIS-3)

22. oktober 2026 oppdatert av: Novartis Pharmaceuticals

An Open-label, Multi-center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)

The purpose of this study was to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy versus SOC anti-cancer therapy for the second-line treatment of mCRC.

This study aimed to explore whether different mechanisms of action could reverse resistance and improve responsiveness to the then-considered SOC anti-cancer therapy in the second-line metastatic colorectal cancer (mCRC) setting.

Studieoversikt

Detaljert beskrivelse

This was an open-label, multi-center, Phase II platform study with both control and investigational arms. Each investigational arm included a Safety Run-In (SRI) phase, followed by an Expansion Part. In the control arm, the standard of care (SoC) anti-cancer therapy consisted of bevacizumab in combination with either modified FOLFOX6 (mFOLFOX6: folinic acid, fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, fluorouracil, and irinotecan).

On July 31, 2023, administration of NIS793 and tislelizumab was halted, and this action was subsequently classified as an Urgent Safety Measure on August 3, 2023, due to an unfavorable benefit/risk profile observed in participants with metastatic colorectal cancer (mCRC).

Each investigational arm included a combination of an investigational drug and the standard of care anti-cancer therapy:

  • Investigational arm #1 included NIS793 in combination with standard of care anti-cancer therapy.
  • Investigational arm #2 included NIS793 in combination with tislelizumab and standard of care anti-cancer therapy.

Safety Run-In Part:

The Safety Run-In (SRI) phase was initiated to confirm the recommended phase 2 dose (RP2D) of the investigational drug(s) in combination with standard of care anti-cancer therapy.

  • For Investigational arm #1, the SRI for both FOLFIRI and mFOLFOX6 regimens was fully enrolled. The RP2D for SRI arm #1 (both FOLFIRI and mFOLFOX6) was declared, and the Expansion Part for arm #1 (both FOLFIRI and mFOLFOX6) was opened and fully enrolled.

    ~ Duration: Each SRI part enrolled up to approximately 20 participants per regimen, with the SRI phase typically lasting until at least 12 evaluable participants completed one 28-day treatment cycle (4 weeks) per regimen.

  • For Investigational arm #2, the SRI for FOLFIRI was fully enrolled, the RP2D was declared, and enrollment for the Expansion Part of arm #2 (FOLFIRI) was ongoing at the time of study termination. The SRI for mFOLFOX6 was also fully enrolled. However, the Data Monitoring Committee (DMC) recommended halting NIS793 and holding tislelizumab treatment on July 31, 2023, and permanently discontinuing tislelizumab on August 3, 2023. Therefore, even after completion of the SRI for arm #2 (mFOLFOX6), the decision was made not to proceed with preparation for a dose confirmation meeting for this group. As a result, no data summaries were produced for investigational arm #2 (mFOLFOX6).

Expansion Part:

The decision to open the Expansion Part of the study was based on dose confirmation of the investigational drug, with available safety, relevant pharmacokinetic (PK), and other relevant clinical and laboratory data from the SRI phase. The Expansion Part ran independently for each standard of care anti-cancer therapy (mFOLFOX6 or FOLFIRI with bevacizumab).

~ Duration: Each Expansion Part was planned to enroll approximately 75 participants per investigational arm and per regimen, with treatment cycles of 28 days each. Participants continued in the Expansion Part until unacceptable toxicity, disease progression, withdrawal of consent, or other protocol-specified discontinuation criteria were met.

After NIS793 and tislelizumab were permanently discontinued, participants were allowed to continue with standard of care therapy as assessed by the Investigator. No additional treatment arms were introduced during the study.

Studietype

Intervensjonell

Registrering (Faktiske)

202

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Novartis Investigative Site
    • Victoria
      • Bendigo, Victoria, Australia, 3550
        • Novartis Investigative Site
    • Western Australia
      • Perth, Western Australia, Australia, 6009
        • Novartis Investigative Site
      • Brussels, Belgia, 1200
        • Novartis Investigative Site
      • Brussels, Belgia, 1000
        • Novartis Investigative Site
      • Leuven, Belgia, 3000
        • Novartis Investigative Site
    • Ontario
      • Brampton, Ontario, Canada, L6R 3J7
        • Novartis Investigative Site
      • Cambridge, Ontario, Canada, N1R 3G2
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H2X 1R9
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Forente stater, 90025
        • The Angeles Clinic and Research Institute
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109-0331
        • University of Michigan Medical
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • WA Uni School Of Med
    • New Jersey
      • East Brunswick, New Jersey, Forente stater, 08816
        • Astera Cancer Center
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Uni Of TX MD Anderson Cancer Cntr
      • San Antonio, Texas, Forente stater, 78229
        • Mays Cancer Center
      • Avignon, Frankrike, 84082
        • Novartis Investigative Site
      • Créteil, Frankrike, 94010
        • Novartis Investigative Site
      • Nantes, Frankrike, 44093
        • Novartis Investigative Site
      • Hong Kong, Hong Kong, 999077
        • Novartis Investigative Site
      • Haifa, Israel, 3109601
        • Novartis Investigative Site
      • Petah Tikva, Israel, 4941492
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20133
        • Novartis Investigative Site
      • Milan, MI, Italia, 20162
        • Novartis Investigative Site
      • Rozzano, MI, Italia, 20089
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 4648681
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japan, 2778577
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki, Kanagawa, Japan, 2168511
        • Novartis Investigative Site
    • Osaka
      • Osaka, Osaka, Japan, 5418567
        • Novartis Investigative Site
    • Toyama
      • Toyama, Toyama, Japan, 9300194
        • Novartis Investigative Site
      • Singapore, Singapore, 119074
        • Novartis Investigative Site
      • Barcelona, Spania, 08035
        • Novartis Investigative Site
      • Barcelona, Spania, 08036
        • Novartis Investigative Site
      • Madrid, Spania, 28040
        • Novartis Investigative Site
    • Barcelona
      • Sabadell, Barcelona, Spania, 08208
        • Novartis Investigative Site
    • Cantabria
      • Santander, Cantabria, Spania, 39008
        • Novartis Investigative Site
      • Cambridge, Storbritannia, CB2 0QQ
        • Novartis Investigative Site
      • Oxford, Storbritannia, OX3 7LE
        • Novartis Investigative Site
    • Grampian Region
      • Aberdeen, Grampian Region, Storbritannia, AB25 2ZN
        • Novartis Investigative Site
      • Sankt Gallen, Sveits, 9007
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 05505
        • Novartis Investigative Site
      • Tainan, Taiwan, 704302
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site
      • Brno, Tsjekkia, 656 53
        • Novartis Investigative Site
      • Hradec Králové, Tsjekkia, 500 05
        • Novartis Investigative Site
      • Prague, Tsjekkia, 140 59
        • Novartis Investigative Site
      • Berlin, Tyskland, 13353
        • Novartis Investigative Site
      • Bochum, Tyskland, 44791
        • Novartis Investigative Site
      • Dresden, Tyskland, 01307
        • Novartis Investigative Site
      • Essen, Tyskland, 45147
        • Novartis Investigative Site
      • Hamburg, Tyskland, 20249
        • Novartis Investigative Site
      • Ulm, Tyskland, 89081
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60488
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Tyskland, 01307
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion criteria:

  • Participants aged 18 or older with histologically or cytologically confirmed (by local laboratory and local clinical guidelines) metastatic colorectal adenocarcinoma that is not amenable to potentially curative surgery in the opinion of the Investigator and progressed on or within 6 months after the last dose of one prior line of systemic anti-cancer therapy administered for metastatic disease.
  • Presence of at least one measurable lesion assessed by CT and/or MRI according to RECIST 1.1.
  • ECOG Performance Status 0 or 1.
  • Adequate organ function (assessed by central laboratory for eligibility).

Key Exclusion criteria:

  • Previously administered systemic immunotherapy (e.g. anti-PD-1, anti-PD-L1/-L2, anti-CTLA-4 antibody) or TGF-β targeted therapies.
  • Microsatellite instability-high/mismatch repair-deficient (mandatory, locally performed), BRAFV600 mutation positive CRC.
  • Known complete or partial DPD enzyme deficiency.
  • For participants treated with irinotecan: Known history or clinical evidence of reduced UGT1A1 activity.
  • Participants who have not recovered from a major surgery performed prior to start of study treatment or have had a major surgery within 4 weeks prior to start of study treatment.
  • Impaired cardiac function or clinically significant cardio-vascular disease.
  • Participants with conditions associated with or history of significant bleeding.
  • Stroke or transient ischemic attack, or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before start of study treatment.
  • Active, known, or suspected autoimmune disease or a documented history of autoimmune disease
  • Pregnant or breast-feeding women, and women of childbearing potential, unless willing to use highly effective contraception methods during treatment and after stopping study treatments as required.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Safety run-in: NIS793+SOC (Investigational arm 1)

Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of NIS793

Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part

Bevacizumab was administered intravenously (IV)

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]

Andre navn:
  • 5FU+Leucovorin+Oxaliplatin

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]

Andre navn:
  • 5FU+Leucovorin+Irinotekan
Eksperimentell: Expansion: NIS793+SOC (Investigational arm 1)

Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in

Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part

Bevacizumab was administered intravenously (IV)

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]

Andre navn:
  • 5FU+Leucovorin+Oxaliplatin

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]

Andre navn:
  • 5FU+Leucovorin+Irinotekan
Aktiv komparator: Expansion: SOC (control arm)

Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)

Bevacizumab was administered intravenously (IV)

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]

Andre navn:
  • 5FU+Leucovorin+Oxaliplatin

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]

Andre navn:
  • 5FU+Leucovorin+Irinotekan
Eksperimentell: Safety run-in: NIS793+Tislelizumab+SOC (Investigational arm 2)

Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab to confirm the RP2D of NIS793

Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part

Bevacizumab was administered intravenously (IV)

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]

Andre navn:
  • 5FU+Leucovorin+Oxaliplatin

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]

Andre navn:
  • 5FU+Leucovorin+Irinotekan

Investigational drug tislelizumab was administered intravenously (IV)

Andre navn:
  • VDT482
Eksperimentell: Expansion: NIS793+Tislelizumab+SOC (Investigational arm 2)

Participants were treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI), NIS793, and tislelizumab at the RP2D for NIS793 defined in the safety run-in

Investigational drug NIS793 was administered intravenously (IV) at the dose and schedule determined in the safety run-in part

Bevacizumab was administered intravenously (IV)

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and oxaliplatin [administered IV]

Andre navn:
  • 5FU+Leucovorin+Oxaliplatin

5-fluorouracil [administered as a continuous infusion], leucovorin [administered IV] (or levoleucovorin [administered IV]), and irinotecan [administered IV]

Andre navn:
  • 5FU+Leucovorin+Irinotekan

Investigational drug tislelizumab was administered intravenously (IV)

Andre navn:
  • VDT482

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
(Safety run-in Part) Number of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.
Tidsramme: Up to 4 weeks

The primary endpoint for the Safety Run-In part was the incidence of dose-limiting toxicities (DLT) during the first 28 days of treatment with investigational drug(s) (NIS793 with or without tislelizumab) and standard of care anti-cancer therapy. Dose tolerability decisions were based on all safety data and a Bayesian Logistic Regression Model (BLRM) using Escalation with Overdose Control (EWOC) criteria. Dose confirmation required at least six evaluable participants, fulfillment of EWOC criteria, and recommendation by Novartis and investigators after reviewing clinical, pharmacokinetic, and laboratory data.

Up to 4 weeks
(Expansion Part) Progression-free Survival (PFS) by Investigator Assessment Per RECIST 1.1
Tidsramme: From randomization up to disease progression or death, assessed up to approximately 11 months

PFS was defined as the time from the date of enrollment (run-in part) or randomization (randomized part) to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

From randomization up to disease progression or death, assessed up to approximately 11 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
(Safety run-in Part) Percentage of Participants With Adverse Events (AEs)
Tidsramme: Through Safety Run-in completion, an average of 6 months

Percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

Through Safety Run-in completion, an average of 6 months
(Safety Run-In) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
Tidsramme: Up to approximately 7 months

Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions or reductions) of investigational drug (NIS793, NIS793 + tislelizumab)

Up to approximately 7 months
(Safety Run-In) Dose Intensity of Investigational Drug
Tidsramme: Up to approximately 7 months

Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

Up to approximately 7 months
(Safety run-in Part) PFS by Investigator Assessment Per RECIST 1.1
Tidsramme: From enrollment up to disease progression or death, assessed up to approximately 7 months

PFS was defined as the time from the date of enrollment to the date of the first documented progression based on investigator assessment and according to RECIST 1.1 or death due to any cause

From enrollment up to disease progression or death, assessed up to approximately 7 months
(Safety run-in Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
Tidsramme: Up to approximately 7 months

ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

Up to approximately 7 months
(Safety run-in Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
Tidsramme: Up to approximately 7 months

DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

Up to approximately 7 months
(Safety run-in Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
Tidsramme: From first documented response up to disease progression or death, assessed up to approximately 7 months

DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

From first documented response up to disease progression or death, assessed up to approximately 7 months
(Safety run-in Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
Tidsramme: From enrollment up to first documented response, assessed up to approximately 7 months

TTR was defined as the duration of time between the date of enrollment and the date of the first documented response of either CR or PR

From enrollment up to first documented response, assessed up to approximately 7 months
(Safety run-in Part) Overall Survival (OS)
Tidsramme: Up to two years

OS was defined as the time from the date of enrollment to the date of death due to any cause

Up to two years
(Safety run-in Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
Tidsramme: Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).

Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab.

Cycle 1 Day 1, Cycle 3 Day 1 (1 cycle = 28 days).
(Safety run-in Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
Tidsramme: Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)

Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 6 Day 1 (1 cycle = 28 days)
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
Tidsramme: Baseline

Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

Baseline
(Safety run-in Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
Tidsramme: From the date of first study drug intake up to approximately 7 months

Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

From the date of first study drug intake up to approximately 7 months
(Expansion Part) Percentage of Participants With Adverse Events (AEs)
Tidsramme: Through Expansion completion, an average of 8 months

The percentage of participants who experienced AEs and SAEs, including changes in laboratory parameters, vital signs, body weight, and cardiac assessments

Through Expansion completion, an average of 8 months
(Expansion Part) Percentage of Participants With Dose Interruptions and Dose Reductions of Investigational Drug
Tidsramme: Up to approximately 11 months

Tolerability was measured by the percentage of subjects who had dose adjustments (interruptions) of the investigational drug (e.g., NIS793, NIS793 + tislelizumab)

Up to approximately 11 months
(Expansion Part) Dose Intensity of Investigational Drug
Tidsramme: Up to approximately 11 months

Tolerability was measured by the dose intensity of the investigational drug (e.g., NIS793, NIS793 + Tislelizumab). Dose intensity was computed as the ratio of the actual cumulative dose received to the actual duration of exposure.

Up to approximately 11 months
(Expansion Part) Overall Response Rate (ORR) by Investigator Assessment Per RECIST 1.1
Tidsramme: Up to approximately 11 months

ORR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator assessment and according to RECIST 1.1

Up to approximately 11 months
(Expansion Part) Disease Control Rate (DCR) by Investigator Assessment Per RECIST 1.1
Tidsramme: Up to approximately 11 months

DCR was defined as the proportion of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), as per investigator assessment and according to RECIST 1.1

Up to approximately 11 months
(Expansion Part) Duration of Response (DOR) by Investigator Assessment Per RECIST 1.1
Tidsramme: From first documented response up to disease progression or death, assessed up to approximately 11 months

DOR was defined as the duration of time between the date of the first documented response (CR or PR) and the date of first documented progression or death due to any cause

From first documented response up to disease progression or death, assessed up to approximately 11 months
(Expansion Part) Time to Response (TTR) by Investigator Assessment Per RECIST 1.1
Tidsramme: From enrollment up to first documented response, assessed up to approximately 11 months

TTR was defined as the duration of time between the date of enrollment and the date of first documented response of either CR or PR

From enrollment up to first documented response, assessed up to approximately 11 months
(Expansion Part) Overall Survival (OS)
Tidsramme: Up to two years

OS was defined as the time from the date of enrollment to the date of death due to any cause

Up to two years
(Expansion Part) Maximum Concentration (Cmax) of NIS793 and Tislelizumab
Tidsramme: Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)

Blood samples were collected at indicated time-points for analysis of Cmax of NIS793 and tislelizumab

Cycle 1 Day 1, Cycle 3 Day 1 (NIS793 only) (1 cycle = 28 days)
(Expansion Part) Trough Concentration (Ctrough) of NIS793 and Tislelizumab
Tidsramme: Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)

Blood samples were collected at indicated time-points for analysis of Ctrough of NIS793 and tislelizumab

Cycle 1 Day 15 (NIS793 only), Cycle 2 Day (tislelizumab only), Cycle 3 Day 1, Cycle 3 Day 15 (NIS793 only), Cycle 4 Day (tislelizumab only), Cycle 6 Day 1 (NIS793 only) (1 cycle = 28 days)
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) at Baseline
Tidsramme: Baseline

Prevalence of NIS793 and Tislelizumab Antidrug antibodies (ADA) at baseline was defined as the proportion of participants who had an ADA positive result at baseline

Baseline
(Expansion Part) NIS793 and Tislelizumab Antidrug Antibodies (ADA) Incidence on Treatment
Tidsramme: From the date of first study drug intake up to approximately 11 months

Incidence of NIS793 and Tislelizumab Antidrug antibodies (ADA) on treatment was defined as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with an ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with a titer that was at least the fold titer change greater than the ADA-positive baseline titer)

From the date of first study drug intake up to approximately 11 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. november 2021

Primær fullføring (Faktiske)

20. januar 2025

Studiet fullført (Faktiske)

20. januar 2025

Datoer for studieregistrering

Først innsendt

28. juni 2021

Først innsendt som oppfylte QC-kriteriene

28. juni 2021

Først lagt ut (Faktiske)

7. juli 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere